In our study, silencing TLR4 inhibited activation of the NLRP3 inflammasome and decreased expression of TGF-β, leading to reduction of atrial fibrosis and susceptibility to AF in vivo and CF proliferation in vitro. The gene discussed is NLRP3; the disease is atrial fibrillation.